Blood test-guided chemotherapy reduction after stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether using a blood test (Signatera) to guide treatment can safely reduce the amount of chemotherapy after surgery for stomach or esophagus cancer. The goal is to see if less treatment is just as effective, based on whether cancer DNA is still detectable in your blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have stomach, esophagus, or gastroesophageal junction cancer that is stage II, III, or IVa.
- You must have already completed a specific chemo-immunotherapy treatment (D-FLOT) and then had surgery to remove the tumor.
- Your surgery must have completely removed the cancer (negative margins).
- You must be eligible to start more chemo-immunotherapy after surgery within 12 weeks.
- You must feel generally well (ECOG 0-1) and have no signs of cancer spread on imaging.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using a blood test that finds tiny bits of cancer DNA to decide if you need extra chemotherapy after surgery. It aims to make treatment more personalized and reduce side effects for people with locally advanced stomach cancer.
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
This trial is testing whether using a blood test to find tiny amounts of cancer DNA after initial treatment can guide decisions about further therapy for people with stomach cancer. The goal is to personalize follow-up treatment to reduce the chance of cancer returning.
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
This trial tests whether measuring tiny amounts of cancer DNA in the blood before standard treatment can help decide who might safely skip chemotherapy before surgery. It aims to see if a less intensive approach works as well for patients with early rectal cancer.
Hear when a new Gastric-Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.